Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01468532 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: docetaxel
DRUG: pasireotide
DRUG: prednisone

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]